| Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology … KJ Pandya, RF Raubertas, PJ Flynn, HE Hynes, RJ Rosenbluth, ... Annals of internal medicine 132 (10), 788-793, 2000 | 423 | 2000 |
| Adaptive designs in clinical drug development—an executive summary of the PhRMA working group P Gallo, C Chuang-Stein, V Dragalin, B Gaydos, M Krams, J Pinheiro Journal of biopharmaceutical statistics 16 (3), 275-283, 2006 | 354 | 2006 |
| Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls P Bauer, F Bretz, V Dragalin, F König, G Wassmer Statistics in Medicine 35 (3), 325-347, 2016 | 230 | 2016 |
| Adaptive designs for dose-finding based on efficacy–toxicity response V Dragalin, V Fedorov Journal of Statistical Planning and Inference 136 (6), 1800-1823, 2006 | 171 | 2006 |
| Adaptive designs: terminology and classification V Dragalin Drug information journal: DIJ/Drug Information Association 40, 425-435, 2006 | 161 | 2006 |
| Adaptive seamless phase II/III designs—background, operational aspects, and examples J Maca, S Bhattacharya, V Dragalin, P Gallo, M Krams Drug information journal 40 (4), 463-473, 2006 | 154 | 2006 |
| Multihypothesis sequential probability ratio tests. II. Accurate asymptotic expansions for the expected sample size VP Dragalin, AG Tartakovsky, VV Veeravalli IEEE Transactions on Information Theory 46 (4), 1366-1383, 2000 | 143 | 2000 |
| Adaptive designs for selecting drug combinations based on efficacy–toxicity response V Dragalin, V Fedorov, Y Wu Journal of Statistical Planning and Inference 138 (2), 352-373, 2008 | 93 | 2008 |
| A simulation study to compare new adaptive dose–ranging designs V Dragalin, B Bornkamp, F Bretz, F Miller, SK Padmanabhan, N Patel, ... Statistics in Biopharmaceutical Research 2 (4), 487-512, 2010 | 87 | 2010 |
| Adaptive Designs for Dose-Finding Studies Based on Sigmoid E max Model V Dragalin, F Hsuan, SK Padmanabhan Journal of Biopharmaceutical Statistics 17 (6), 1051-1070, 2007 | 86 | 2007 |
| Two‐stage design for dose‐finding that accounts for both efficacy and safety V Dragalin, VV Fedorov, Y Wu Statistics in Medicine 27 (25), 5156-5176, 2008 | 73 | 2008 |
| Kullback–Leibler divergence for evaluating bioequivalence V Dragalin, V Fedorov, S Patterson, B Jones Statistics in medicine 22 (6), 913-930, 2003 | 53 | 2003 |
| The design and analysis of 2-CUSUM procedure V Dragalin Communications in Statistics-Simulation and Computation 26 (1), 67-81, 1997 | 44 | 1997 |
| A simple and effective scanning rule for a multi-channel system V Dragalin Metrika 43, 165-182, 1996 | 43 | 1996 |
| Adaptive sequential tests for composite hypotheses VP Dragalin, AA Novikov Survey of Applied and Industrial Mathematics 6, 387-398, 1999 | 39 | 1999 |
| Adaptive and model-based dose-ranging trials: quantitative evaluation and recommendations. White paper of the PhRMA working group on adaptive dose-ranging studies J Pinheiro, F Sax, Z Antonijevic, B Bornkamp, F Bretz, C Chuang-Stein, ... Statistics in Biopharmaceutical Research 2 (4), 435-454, 2010 | 38 | 2010 |
| Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop M Krams, CF Burman, V Dragalin, B Gaydos, AP Grieve, J Pinheiro, ... Journal of biopharmaceutical statistics 17 (6), 957-964, 2007 | 38 | 2007 |
| Designing issues in confirmatory adaptive population enrichment trials G Wassmer, V Dragalin Journal of biopharmaceutical statistics 25 (4), 651-669, 2015 | 35 | 2015 |
| Optimality of generalized Cusum procedure in quickest detection problem VP Dragalin Proceedings of the Steklov Institute of Mathematics-AMS Translation 202, 107-120, 1994 | 34 | 1994 |
| Simulation practices for adaptive trial designs in drug and device development C Mayer, I Perevozskaya, S Leonov, V Dragalin, Y Pritchett, A Bedding, ... Statistics in Biopharmaceutical Research 11 (4), 325-335, 2019 | 29 | 2019 |
